RBC on Boston Scientific (BSX) Long-Range Plan Released Earlier at Investor Day, 'we are encouraged
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
JPMorgan on Boston Scientific (BSX) Investor Day Update: 'reinforces our bullish view on Boston'
September 20, 2023 10:52 AM EDTJPMorgan analyst Robbie Marcus reiterated an Overweight rating on Boston Scientific (NYSE: BSX)
The analyst comments "Management kicked off the Boston Scientific biennial analyst day with an update to its LRP (long range plan) for 2024-2026 that now points towards: (1) sales CAGR of +8-10%... More
AutoZone, Starbucks and Block fall premarket; Dell, Tesla rise
September 19, 2023 8:04 AM EDTInvesting.com -- U.S. futures traded marginally higher Tuesday, as investors await the start of the crucial two-day Federal Reserve meeting, which could set the tone for weeks to come.
Here are some of the biggest premarket U.S. stock movers today:
Instacart is set to make its Nasdaq debut after the... More
Boston Scientific (BSX) to Acquire Relievant Medsystems for Over $850 Million
September 19, 2023 7:01 AM EDTBoston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three... More



